^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cabotamig (ARB202)

    i
    Other names: ARB202, ARB 202, ARB-202
    Associations

    News

    Trials
    Company:
    Arbele
    Drug class:
    CD3 agonist, CDH17 inhibitor
    Related drugs:
    Associations

    News

    Trials
    22d
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=33, Completed, Arbele Pty Ltd | Recruiting --> Completed | N=68 --> 33 | Trial completion date: May 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    7ms
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, Arbele Pty Ltd | Trial completion date: Aug 2025 --> May 2026 | Trial primary completion date: Nov 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    almost4years
    Treatment of ARB202 Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, Arbele Pty Ltd
    New P1 trial
    |
    IL2 (Interleukin 2)
    |
    CDH1 expression
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)